Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.
BACKGROUND
Afghanistan's national guidelines recommend chloroquine for the treatment of Plasmodium vivax infection, the parasite responsible for the majority of its malaria burden. Chloroquine resistance in P. vivax is emerging in Asia. Therapeutic responses across Afghanistan have not been evaluated in detail.


METHODS
Between July 2007 and February 2009, an open-label, randomized controlled trial of chloroquine and dihydroartemisinin-piperaquine in patients aged three months and over with slide-confirmed P. vivax mono-infections was conducted. Consistent with current national guidelines, primaquine was not administered. Subjects were followed up daily during the acute phase of illness (days 0-3) and weekly until day 56. The primary endpoint was the overall cumulative parasitological failure rate at day 56 after the start of treatment, with the hypothesis being that dihydroartemisinin-piperaquine was non-inferior compared to chloroquine (Delta = 5% difference in proportion of failures).


RESULTS
Of 2,182 individuals with positive blood films for P. vivax, 536 were enrolled in the trial. The day 28 cure rate was 100% in both treatment groups. Parasite clearance was more rapid with dihydroartemisinin-piperaquine than chloroquine. At day 56, there were more recurrent infections in the chloroquine arm (8.9%, 95% CI 6.0-13.1%) than the dihydroartemisinin-piperaquine arm (2.8%, 95% CI 1.4-5.8%), a difference in cumulative recurrence rate of 6.1% (2-sided 90%CI +2.6 to +9.7%). The log-rank test comparing the survival curves confirmed the superiority of dihydroartemisinin-piperaquine over chloroquine (p = 0.003). Multivariate analysis showed that a lower initial haemoglobin concentration was also independently associated with recurrence. Both regimens were well tolerated and no serious adverse events were reported.


CONCLUSIONS
Chloroquine remains an efficacious treatment for the treatment of vivax malaria in Afghanistan. In a setting where radical therapy cannot be administered, dihydroartemisinin-piperaquine provides additional benefit in terms of post-treatment prophylaxis, reducing the incidence of recurrence from 4-8 weeks after treatment.
Awab
Ghulam Rahim
GR
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Pukrittayakamee
Sasithon
S
Imwong
Mallika
M
Dondorp
Arjen M
AM
Woodrow
Charles J
CJ
Lee
Sue Jean
SJ
Day
Nicholas P J
NP
Singhasivanon
Pratap
P
White
Nicholas J
NJ
Kaker
Faizullah
F
D000293:Adolescent; D000346:Afghanistan; D000962:Antimalarials / Q000627:therapeutic use*; D037621:Artemisinins / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002738:Chloroquine / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D016780:Malaria, Vivax / Q000188:drug therapy* / Q000469:parasitology; D008297:Male; D015999:Multivariate Analysis; D010966:Plasmodium vivax / Q000187:drug effects* / Q000302:isolation & purification; D011446:Prospective Studies; D011804:Quinolines / Q000627:therapeutic use*; D012008:Recurrence; D016896:Treatment Outcome; D010879:Piperazines
D000962:Antimalarials; D037621:Artemisinins; D002738:Chloroquine; D011804:Quinolines; C039060:artenimol; C034759:piperaquine; D010879:Piperazines
Antimicrob Agents Chemother. 2005 Dec;49(12):5127-8
16304183
Acta Trop. 2004 Feb;89(3):351-6
14744561
J Egypt Soc Parasitol. 2008 Dec;38(3):679-92
19209754
Antimicrob Agents Chemother. 2000 Jun;44(6):1680-5
10817728
Clin Infect Dis. 2007 Apr 15;44(8):1067-74
17366451
Clin Infect Dis. 2002 Dec 15;35(12):1469-76
12471565
JAMA. 2007 May 23;297(20):2201-9
17519409
Trans R Soc Trop Med Hyg. 2004 Mar;98(3):168-73
15024927
Trans R Soc Trop Med Hyg. 2007 Apr;101(4):351-9
17028048
Trends Parasitol. 2002 Oct;18(10):458-64
12377597
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):79-87
18165478
Trans R Soc Trop Med Hyg. 1994 Jun;88 Suppl 1:S41-3
8053024
JAMA. 2006 Mar 8;295(10):1152-60
16522836
Am J Trop Med Hyg. 2001 Jan-Feb;64(1-2 Suppl):97-106
11425182
Lancet. 2005 Apr 23-29;365(9469):1506-12
15850637
Lancet. 2007 Mar 3;369(9563):757-765
17336652
J Infect Dis. 2007 Apr 1;195(7):934-41
17330782
Am J Trop Med Hyg. 2003 Apr;68(4):416-20
12875290
Emerg Infect Dis. 2006 Oct;12(10):1600-2
17176583
Emerg Infect Dis. 2009 Nov;15(11):1753-9
19891862
Trans R Soc Trop Med Hyg. 2007 Nov;101(11):1081-7
17707447
N Engl J Med. 2008 Dec 11;359(24):2545-57
19064624
Emerg Infect Dis. 2007 Sep;13(9):1402-4
18252122
Methods Mol Biol. 1996;50:263-91
8751365
Lancet. 1999 Jul 10;354(9173):162
10408515
Ann Trop Med Parasitol. 2004 Jan;98(1):85-8
15000735
PLoS One. 2008 Aug 06;3(8):e2861
18682739
Trans R Soc Trop Med Hyg. 1999 Nov-Dec;93(6):641-3
10717755
Malar J. 2006 Dec 22;5:127
17187673
Malar J. 2010 Mar 14;9:75
20226087
Indian J Malariol. 1957 Mar;11(1):73-126
13438535
Antimicrob Agents Chemother. 2008 Jan;52(1):237-43
17967917
Lancet. 1999 Aug 14;354(9178):546-9
10470698
Trop Med Int Health. 2005 Jun;10(6):521-9
15941414
Am J Trop Med Hyg. 1997 Jun;56(6):627-31
9230793
Am J Trop Med Hyg. 2009 Aug;81(2):338-42
19635895
J Infect Dis. 2007 Apr 1;195(7):927-33
17330781
Clin Microbiol Rev. 2009 Jul;22(3):508-34
19597012